The backers remained undisclosed.
The company intends to use the funds to expand commercial operations, sales force, PuraPly product line, and develop new products in the wound care and surgical fields.
Led by Gary S. Gillheeney, Sr., President & CEO, Organogenesis provides provides advanced wound care products for bio-active wound healing and soft tissue regeneration. The portfolio includes FDA-approved Apligraf® and Dermagraft®, for bio-active wound healing and recently launched, FDA-cleared PuraPly Antimicrobial™, which advances wound management for a wide variety of wound types.
The product portfolio expansion includes several additions to the PuraPly wound management line, the launch in the next year of an FDA-approved Class III PMA burn treatment, and new product offerings from the FortaFlex™ collagen matrix technology platform for soft tissue reinforcement.
FinSMEs
14/04/2016